%0 Journal Article %A Lisa J. Krüger %A Julian A.F. Klein %A Frank Tobian %A Mary Gaeddert %A Federica Lainati %A Sarah Klemm %A Paul Schnitzler %A Ralf Bartenschlager %A Berati Cerikan %A Christopher J. Neufeldt %A Olga Nikolai %A Andreas K. Lindner %A Frank P. Mockenhaupt %A Joachim Seybold %A Terry C. Jones %A Victor M. Corman %A Nira R. Pollock %A Britta Knorr %A Andreas Welker %A Margaretha de Vos %A Jilian A. Sacks %A Claudia M. Denkinger %A for the study team %T Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device for SARS-CoV-2 %D 2021 %R 10.1101/2021.03.02.21252430 %J medRxiv %P 2021.03.02.21252430 %X Background Rapid antigen-detecting tests (Ag-RDTs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transform pandemic control. Thus far, sensitivity (≤85%) of lateral-flow assays has limited scale-up. Conceivably, microfluidic immunofluorescence Ag-RDTs could increase sensitivity for SARS-CoV-2 detection.Materials and Methods This multi-centre diagnostic accuracy study investigated performance of the microfluidic immunofluorescence LumiraDx™ assay, enrolling symptomatic and asymptomatic participants with suspected SARS-CoV-2 infection. Participants collected a supervised nasal mid-turbinate (NMT) self-swab for Ag-RDT testing, in addition to a professionally-collected nasopharyngeal (NP) swab for routine testing with reverse transcriptase polymerase chain reaction (RT-PCR). Results were compared to calculate sensitivity and specificity. Sub-analyses investigated the results by viral load, symptom presence and duration. An analytical study assessed exclusivity and limit-of-detection (LOD). In addition, we evaluated ease-of-use.Results Study conduct was between November 2nd 2020 and January 21st 2021. 761 participants were enrolled, with 486 participants reporting symptoms on testing day. 120 out of 146 RT-PCR positive cases were detected positive by LumiraDx™, resulting in a sensitivity of 82.2% (95% CI: 75.2%-87.5%). Specificity was 99.3% (CI: 98.3-99.7%). Sensitivity was increased in individuals with viral load ≥ 7 log10 SARS-CoV2 RNA copies/ml (93.8%; CI: 86.2%-97.3%). Testing against common respiratory commensals and pathogens showed no cross-reactivity and LOD was estimated to be 2-56 PFU/mL. The ease-of-use-assessment was favourable for lower throughput settings.Conclusion The LumiraDx™ assay showed excellent analytical sensitivity, exclusivity and clinical specificity with good clinical sensitivity using supervised NMT self-sampling.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021220Funding StatementThe study was supported by the Ministry of Science, Research and Arts of the State of Baden-Wuerttemberg, Germany and internal funds from the Heidelberg University Hospital and University Hospital Charité - Universitaetsmedizin Berlin as well as grants from UK Department of International Development (DFID, recently replaced by FCMO), grants from World Health Organization (WHO), grants from Unitaid to Foundation of New Diagnostics (FIND). The testing devices and all components were provided by the manufacturer. T.C.J. is in part funded through NIAID-NIH CEIRS contract HHSN272201400008C. The manufacturer and funders had no input into the study protocol, the analysis or interpretation of the results. The corresponding author had access to all data at all time.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved in March 2020 by the ethical review committee at the Heidelberg University Hospital for the two study sites Heidelberg and Berlin in Germany (Registration number S-180/2020). All participants provided written informed consent prior to inclusion in the study. The study was registered in the German clinical trial registry with the registration number DRKS00021220.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe are currently working on the availability of the dataset in a file repository and will make a link available as soon as we have completed the process %U https://www.medrxiv.org/content/medrxiv/early/2021/03/05/2021.03.02.21252430.full.pdf